Efficacy and Safety of Selexipag Treatment in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease. [PDF]
Dagher C+5 more
europepmc +1 more source
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro+15 more
wiley +1 more source
2025 SELECT ABSTRACTS FROM THE 18<sup>th</sup> ANNUAL INTERNATIONAL CONFERENCE ON NEONATAL AND CHILDHOOD PULMONARY VASCULAR DISEASE. [PDF]
europepmc +1 more source
Integrative proteomics and metabolomics reveal important pathways and potential biomarkers in high-altitude pulmonary hypertension. [PDF]
Dan-Zeng ZG+8 more
europepmc +1 more source
Association between prealbumin levels and pulmonary hypertension in peritoneal dialysis patients: a single-center retrospective cohort study. [PDF]
Wang Y+7 more
europepmc +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia+2 more
wiley +1 more source
Serum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography. [PDF]
Du J+6 more
europepmc +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo+7 more
wiley +1 more source
Inhaled nitric oxide as an independent intervention to lower the risk of bronchopulmonary dysplasia in preterm infants (< 33 weeks) with pulmonary hypertension within the initial 3 days of life. [PDF]
Azad T+11 more
europepmc +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller+8 more
wiley +1 more source